289 related articles for article (PubMed ID: 22425801)
1. Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria.
Peces R; Aguilar A; Vega C; Cuesta E; Peces C; Selgas R
Nefrologia; 2012; 32(2):160-5. PubMed ID: 22425801
[TBL] [Abstract][Full Text] [Related]
2. A successful treatment of life-threatening bleeding from polycystic kidneys with antifibrinolytic agent tranexamic acid.
Vujkovac B; Sabovic M
Blood Coagul Fibrinolysis; 2006 Oct; 17(7):589-91. PubMed ID: 16988557
[TBL] [Abstract][Full Text] [Related]
3. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: tranexamic acid in life-threatening haematuria.
Emerg Med J; 2015 Feb; 32(2):168-9. PubMed ID: 25605262
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Persistent Gross Hematuria with Tranexamic Acid in Autosomal Dominant Polycystic Kidney Disease.
Yao Q; Wu M; Zhou J; Zhou M; Chen D; Fu L; Bian R; Xing X; Sun L; Hu X; Li L; Dai B; Wüthrich RP; Ma Y; Mei CL
Kidney Blood Press Res; 2017; 42(1):156-164. PubMed ID: 28395294
[TBL] [Abstract][Full Text] [Related]
5. Tranexamic acid and thrombosis.
Prescrire Int; 2013 Jul; 22(140):182-3. PubMed ID: 23951593
[TBL] [Abstract][Full Text] [Related]
6. Complications of autosomal dominant polycystic kidney disease in 50 haemodialysed patients. A case-control study. The U.C.L. Collaborative Group.
Christophe JL; van Ypersele de Strihou C; Pirson Y
Nephrol Dial Transplant; 1996 Jul; 11(7):1271-6. PubMed ID: 8672022
[TBL] [Abstract][Full Text] [Related]
7. Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study.
McGovern AP; Jones S; van Vlymen J; Saggar AK; Sandford R; de Lusignan S
BMC Nephrol; 2014 Nov; 15():182. PubMed ID: 25412767
[TBL] [Abstract][Full Text] [Related]
8. [Co-inheritance of autosomal dominant polycystic kidney disease and sickle cell trait in African Americans].
Peces R; Peces C; Cuesta-López E; Vega-Cabrera C; Azorín S; Pérez-Dueñas V; Selgas R
Nefrologia; 2011; 31(2):162-8. PubMed ID: 21461009
[TBL] [Abstract][Full Text] [Related]
9. Life-Threatening Retroperitoneal Hemorrhage Following Cyst Rupture in Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Case Report.
Duriseti P; Radhakrishnan Y; Chedid M; Hanna C; Potrezke TA; Chebib FT
Am J Case Rep; 2023 Feb; 24():e938889. PubMed ID: 36843311
[TBL] [Abstract][Full Text] [Related]
10. Native nephrectomy for autosomal dominant polycystic kidney disease: before or after kidney transplantation?
Kirkman MA; van Dellen D; Mehra S; Campbell BA; Tavakoli A; Pararajasingam R; Parrott NR; Riad HN; McWilliam L; Augustine T
BJU Int; 2011 Aug; 108(4):590-4. PubMed ID: 21166760
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
12. Experience with autosomal dominant polycystic kidney disease in patients before and after renal transplantation: a 7-year observation.
Sulikowski T; Tejchman K; Zietek Z; Rózański J; Domański L; Kamiński M; Sieńko J; Romanowski M; Nowacki M; Pabisiak K; Kaczmarczyk M; Ciechanowski K; Ciechanowicz A; Ostrowski M
Transplant Proc; 2009; 41(1):177-80. PubMed ID: 19249508
[TBL] [Abstract][Full Text] [Related]
13. Haematuria in ADPKD: not always benign. Be aware!
Agarwal M; Sokhal AK; Kumar M; Goel S
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993351
[TBL] [Abstract][Full Text] [Related]
14. Oral tranexamic acid as a novel treatment option for persistent haematuria in patients with sickle cell disease.
Davis NF; McGuire BB; Lawlor L; O'Gorman P; O'Malley KJ; Fitzpatrick JM
Ann Hematol; 2010 Nov; 89(11):1179-80. PubMed ID: 20358201
[No Abstract] [Full Text] [Related]
15. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
[TBL] [Abstract][Full Text] [Related]
16. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
17. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.
Later AF; Maas JJ; Engbers FH; Versteegh MI; Bruggemans EF; Dion RA; Klautz RJ
Eur J Cardiothorac Surg; 2009 Aug; 36(2):322-9. PubMed ID: 19250838
[TBL] [Abstract][Full Text] [Related]
18. The effect of long-term, low-dose tranexamic acid treatment on platelet dysfunction and haemoglobin levels in haemodialysis patients.
Sabovic M; Zupan IP; Salobir B; Zupan I; Cernelc P; Lavre J; Vujkovac B
Thromb Haemost; 2005 Dec; 94(6):1245-50. PubMed ID: 16411401
[TBL] [Abstract][Full Text] [Related]
19. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography in the diagnostic pathway for intracystic infection in adpkd and "cystic" kidneys. a case series.
Piccoli GB; Arena V; Consiglio V; Deagostini MC; Pelosi E; Douroukas A; Penna D; Cortese G
BMC Nephrol; 2011 Sep; 12():48. PubMed ID: 21957932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
